|Year : 2020 | Volume
| Issue : 6 | Page : 73
Inflammatory myositis - Foray into the future
Neil McHugh1, Latika Gupta2
1 Department of Pharmacy and Pharmacology, Royal National Hospital for Rheumatic Diseases, Bath, UK
2 Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
|Date of Submission||17-Nov-2020|
|Date of Acceptance||16-Dec-2020|
|Date of Web Publication||18-Jan-2021|
Dr. Latika Gupta
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
McHugh N, Gupta L. Inflammatory myositis - Foray into the future. Indian J Rheumatol 2020;15:73
Idiopathic inflammatory myositis (IIM) is rare and heterogeneous, and the field is rapidly evolving with newer insights being offered by the discovery of newer autoantibodies and a greater understanding of the disease through collaborative studies on the rare groups of diseases. Through this special supplement on myositis, we hope to review recent literature for key insights into the various forms of disease and management in the clinics. We begin with a history of myositis research from India and go on to discuss the never-ending debate on the utility of autoantibodies versus biopsy, followed by discussions on the pathogenesis of IIM and the various overlap forms of myositis, cancer-associated myositis, statin-associated muscle disorders, and sporadic inclusion body myositis and controversies in the management of juvenile dermatomyositis. The emerging spectrum of the antisynthetase syndrome and rapidly progressive lung disease in the setting of IIM is covered in depth by two scoping reviews on the subject.
Myositis being a rare disease, collaborative efforts are needed to gather meaningful multicenter data. Unified case-record forms (CRFs) and biobanking are essential to such efforts. Two-method papers describe the setting up of a biobank and digitally archived dataset collected on a unified CRF in India. Further, we discuss original studies on the differential diagnosis of polymyositis in the clinic, a new biomarker on IIM, and the utility of intravenous immunoglobulin in the Indian setting. Three case reports highlight an atypical presentation of the antisynthetase syndrome and sarcoidosis-associated myositis and the successful treatment of juvenile dermatomyositis with tacrolimus.
While physician perspectives are oft explored, patient perspectives are less discussed and poorly understood. In the post-COVID era of social distancing and remote chronic care, patient-reported outcome measures may be the new norm. Moreover, fighting a chronic illness may entail more than meets the eye, and a better understanding of the mental and emotional struggle and community support needed to help these individuals may go a long way in improving patient care. We have featured unique patient perspectives, in an interview with Amber O' Connor, and another one by a student clinician, highlighting the issues that are less discussed.
Scientific writing is an art, and with this supplement, we have also tried to revive some art forms such as cartoons and poetry relevant to the disease. As they say, a picture is a poem without words, and we hope to explore both domains of visual and prose art in this new endeavor of the likes of JAMA and Lancet.
We hope that this supplement will delight the readers with up-to-date information and help them gather fresh perspectives!
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.